AndreaBozzo/ceres-open-data-index huggingface dataset:
Which treatment for low back pain? A factorial randomised controlled trial comparing intravenous analgesics with oral analgesics in the emergency department and a centrally acting muscle relaxant with placebo over three days [ISRCTN09719705]

Background
          About two thirds of adults suffer from backpain at some time during their life. In the emergency room many patients with acute back pain are treated with intravenous non-steroidal analgesics. Whether this treatment is superior to oral administration of non-steroidal analgesics is unknown. Intravenous administration, however, requires considerable amounts of resources and accounts for high workload in busy clinics. In the further course centrally acting muscle relaxants are prescribed but the effectiveness remains unclear. The objective of this study is on the one hand to compare the effectiveness of intravenous with oral non-steroidal analgesics for acute treatment and on the other hand to compare the effectiveness of a centrally active muscle relaxant with placebo given for three days after presentation to the ED (emergency department).
        
        
          Methods/Design
          This study is intended as a randomised controlled factorial trial mainly for two reasons: (1) the sequence of treatments resembles the actual proceedings in every-day clinical practice, which is important for the generalisability of the results and (2) this design allows to take interactions between the two sequential treatment strategies into account. There is a patient preference arm included because patients preference is an important issue providing valuable information: (1) it allows to assess the interaction between desired treatment and outcome, (2) results can be extrapolated to a wider group while (3) conserving the advantages of a fully randomised controlled trial.
        
        
          Conclusion
          We hope to shed more light on the effectiveness of treatment modalities available for acute low back pain.
Health Home Utilization Measures: Beginning 2013

This dataset contains measures of Health Home member service utilization. The New York State Department of Health (NYSDOH) collects annual data on children’s and adults’ use of health services. This information complements the Health Home Quality Measures information collected for the State Plan Amendment (SPA) and Core Set of health care quality measures. Utilization measures are designed to capture the frequency of certain services. NCQA does not view higher or lower services counts as better or worse performance. 

The data used in the Health Home Utilization Measures are taken from the following sources: 
•	Medicaid Data Mart: Claims and encounters data generated from the Medicaid Data Warehouse (MDW).

Please refer to the Overview document for additional information.
AFCARS Report #30

This report provides preliminary estimates of Adoption and Foster Care Analysis and Reporting System (AFCARS) data for FY 2022. As states are permitted to resubmit AFCARS data, the estimates may change over time. This report reflects all AFCARS data received as of May 9, 2023 related to AFCARS reporting periods through September 30, 2022.

Metadata-only record linking to the original dataset. Open original dataset below.
Fibroblasts and monocyte macrophages contract and degrade three-dimensional collagen gels in extended co-culture

Background
          Inflammatory cells are believed to play a prominent role during tissue repair and remodeling. Since repair processes develop and mature over extended time frames, the present study was designed to evaluate the effect of monocytes and fibroblasts in prolonged culture in three-dimensional collagen gels.
        
        
          Methods
          Blood monocytes from healthy donors and human fetal lung fibroblasts were cast into type I collagen gels and maintained in floating cultures for three weeks.
        
        
          Results
          Fibroblast-mediated gel contraction was initially inhibited by the presence of monocytes (P < 0.01). However, with extended co-culture, contraction of the collagen gels was greatly augmented (P < 0.01). In addition, with extended co-culture, degradation of collagen in the gels occurred. The addition of neutrophil elastase to the medium augmented both contraction and degradation (P < 0.01). Prostaglandin E2 production was significantly increased by co-culture and its presence attenuated collagen degradation.
        
        
          Conclusion
          The current study, therefore, demonstrates that interaction between monocytes and fibroblasts can contract and degrade extracellular matrix in extended culture.
Physiological function of the maltose operon regulator, MalR, in

Background
          Maltose metabolism is initiated by an ATP-dependent permease system in Lactococcus lactis. The subsequent degradation of intracellular maltose is performed by the concerted action of Pi-dependent maltose phosphorylase and β-phosphoglucomutase. In some Gram-positive bacteria, maltose metabolism is regulated by a maltose operon regulator (MalR), belonging to the LacI-GalR family of transcriptional regulators. A gene presumed to encode MalR has been found directly downstream the maltose phosphorylase-encoding gene, malP in L. lactis. The purpose of this study was to investigate the physiological role of the MalR protein in maltose metabolism in L. lactis.
        
        
          Results
          A L. lactis ssp. lactis mutant, TMB5004, deficient in the putative MalR protein, was physiologically characterised. The mutant was not able to ferment maltose, while its capability to grow on glucose as well as trehalose was not affected. The activity of maltose phosphorylase and β-phosphoglucomutase was not affected in the mutant. However, the specific maltose uptake rate in the wild type was, at its lowest, five times higher than in the mutant. This difference in maltose uptake increased as the maltose concentration in the assay was increased.
        
        
          Conclusion
          According to amino acid sequence similarities, the presumed MalR is a member of the LacI-GalR family of transcriptional regulators. Due to the suggested activating effect on maltose transport and absence of effect on the activities of maltose phosphorylase and β-phosphoglucomutase, MalR of L. lactis is considered rather as an activator than a repressor.
Patent AT-E401805-T1: [Translated] ENGAGEMENT ELEMENT FOR FASTENING ITEMS SUCH AS FOOTWEAR AND OTHER FOOTWEAR ITEMS

Engaging elements may be included in foot-receiving devices, such as footwear, bindings, clips, or the like. Such elements may include a bimodal spring member movable between two independent stable positions and an arm that moves in response to the bimodal spring member changing between its stable positions. The engaging elements additionally may include a retaining element extending from the arm and/or an arm/bimodal spring interface that induces changes in position of the arm in response to the bimodal spring member changing its stable position. The bimodal spring member, the arm, the retaining element, and/or the arm/bimodal spring interface may form an integral unit. Additionally, methods of engaging a foot-receiving device with a user's foot are disclosed. Such methods may include: (a) orienting a bimodal spring member in a first stable position to place a foot-engaging portion of the foot-receiving device in a foot-accepting position, and (b) moving the bimodal spring member from the first stable position to a second stable position to move the foot-engaging portion of the foot-receiving device to a foot-engaging position.
National Estimates of Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts

Excel file with national estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts, covering 2004-2011.  Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.
Compound 528898: Guaifenesin M (OH)

Chemical compound data from PubChem database. IUPAC Name: 4-(2,3-dihydroxypropoxy)benzene-1,3-diol. Molecular Formula: C9H12O5. Molecular Weight: 200.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400773-T1: [Translated] LAMP BODY FOR A MEDICAL LAMP AND USE THEREOF

The first lamp (3) is a gas discharge lamp, the second (4) is incandescent. Their end caps are held and connected in sockets (1, 15), forming a unit (16) which can be turned about an axis. The unit is released by unlocking, allowing it to be rotated by a pre-tensioned torsion spring (8). The spring is connected between the pivoting unit and a fixed part of the lamp body.
Compound 526979: (10,13-Dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) formate

Chemical compound data from PubChem database. IUPAC Name: (10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl) formate. Molecular Formula: C20H30O3. Molecular Weight: 318.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CCWIS IV-E Eligibility Requirements Presentation

This DSS presentation describes the Comprehensive Child Welfare Information System (CCWIS) IV-E Eligibility Requirements as defined by Federal Regulations 45 CFR 1355.52(g). Related CCWIS data, data exchange, and data exchange standard requirements as defined by Federal Regulations 45 CFR 1355.52(b), 1355.52(e), and 1355.52(f) are also covered.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525673: p-Bromobenzylidene-pentyl-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-bromophenyl)-N-pentylmethanimine. Molecular Formula: C12H16BrN. Molecular Weight: 254.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400875-T1: [Translated] MOBILE DEVICE USING A REMOVABLE MEDIUM TO PLAY A CONTENT

A service that provides playback of media content, that may include advertising content, to a user. The system comprises device, that may be a portable wireless device, where the wireless device has a media drive and an application that reads content from a medium inserted in the media drive. The system further comprises a service that communicates with the wireless device via a wireless network. The service provides control commands to the application program for controlling playback of content from the medium when inserted in the media drive. The service may also provide advertising content to the user based on a user profile. A fee may be paid for the delivery of the content and/or the advertising to the user.
Delaware (DE)

This report presents Delaware\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Delaware for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
2019-2020 National Surveys on Drug Use and Health: Model-Based Estimated Totals (in Thousands)

State estimates for these years are no longer available due to methodological concerns with combining 2019 and 2020 data. We apologize for any inconvenience or confusion this may causeBecause of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the two years could be misleading.For more detail on this decision, see the 2019-2020state data page.
Research Article: Journal of Biomedicine and Biotechnology

Tamoxifen, a potent anticancer agent known to interrupt the
enhanced estrogen activity of malignant mammary gland cells, was recently approved by the Food and Drug Administration (FDA) for the treatment of breast cancer. In this investigation, the toxic effects of tamoxifen were evaluated through cell multiplication, and cytological, surface ultrastructural, and biochemical studies on human cervical carcinoma cells (HeLa) and/or murine erythroleukemic (MEL) cells (BB-88). Tamoxifen treatment
demonstrated an inhibitory effect on HeLa cell multiplication at lower concentrations and toxicity at higher concentrations and longer treatment durations. The drug also triggered morphological and biochemical changes as revealed by light microscopy, scanning electron microscopy (SEM), fluorescence microscopy, Nucleosome ELISA, and the DNA smear pattern. Cytological observations showed nuclear condensation, cell shrinkage, multinucleation, and apoptotic bodies. Surface ultrastructure of tamoxifen treated cells examined under the SEM revealed abnormalities such as
membrane blebbing, holes, and cytoplasmic extrusions, all of which are characteristics of programmed cell death (apoptosis). Redistribution of the membrane phospholipid phosphatidylserine (PS) from the protoplasmic surface of the plasma membrane to the cell surface was identified using annexin V-enhanced green fluorescent protein (EGFP) in tamoxifen treated MEL BB-88 cells, a general feature of cells undergoing apoptosis. Tamoxifen
treated cells demonstrated internucleosomal damages of the genomic DNA and DNA fragmentations, evidenced by an increase in free nucleosomes, and distinctive DNA smear patterns on the agarose gel.
NOHSS Child Indicators

Data for School year-end 1994 through year-end 2020.  State oral health surveys are the data sources for these indicators. States periodically conduct independent screening surveys of a probability sample designed to be representative of all third-grade students in the state. Some states also conduct surveys of students in other grades in school, or of Head Start program enrollees. This surveillance activity is voluntary. States submit their data to the Association of State and Territorial Dental Directors (ASTDD), where the survey design and data collected are reviewed for quality and against the criteria for inclusion in NOHSS, before being sent to CDC for inclusion in Oral Health Data. For more information, see: http://www.cdc.gov/oralhealthdata/overview/childIndicators/
New York-Northern New Jersey-Long Island, NY-NJ-PA

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the New York-Northern New Jersey-Long Island, NY-NJ-PA metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the New York-Northern New Jersey-Long Island metro area, New York, and the U.S. overall.
Conservation of the COP9/signalosome in budding yeast

Background
          The COP9/signalosome (CSN), a multiprotein complex consisting of eight subunits, is implicated in a wide variety of regulatory processes including cell cycle control, signal transduction, transcriptional activation, and plant photomorphogenesis. Some of these functions have been linked to CSN-associated enzymes, including kinases and an activity that removes the ubiquitin-like protein NEDD8/Rub1p from the cullin subunit of E3 ligases. CSN is highly conserved across species from fission yeast to humans, but sequence comparison has failed to identify the complex in budding yeast, except for a putative CSN5 subunit called Rri1p.
        
        
          Results
          We show that disruption of four budding yeast genes, PCI8 and three previously uncharacterized ORFs, which encode proteins interacting with Rrr1p/Csn5p, each results in the accumulation of the cullin Cdc53p exclusively in the Rub1p-modified state. This phenotype, which resembles that of fission yeast csn mutants, is due to a biochemical defect in deneddylation that is complemented by wild-type cell lysate and by purified human CSN in vitro. Although three of the four genes encode proteins with PCI domains conserved in metazoan CSN proteins, their disruption does not confer the DNA damage sensitivity described in some fission yeast csn mutants.
        
        
          Conclusions
          Our studies present unexpected evidence for the conservation of a functional homologue of the metazoan CSN, which mediates control of cullin neddylation in budding yeast.
Compound 529128: 1-Butanamine, 3-methyl, mono-TMS

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-N-trimethylsilylbutan-1-amine. Molecular Formula: C8H21NSi. Molecular Weight: 159.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Health and Aging Trends Study (NHATS) – Vision and Eye Health Surveillance System (VEHSS)

VEHSS analyzed NHATS public use data to calculate the prevalence of visual acuity and contrast sensitivity loss. Data are based on NHATS round 12, which was collected in 2022. We defined subgroup thresholds based on the VEHSS case definitions for Vision Loss and Blindness.

NHATS is a health examination survey conducted on a nationally representative sample of Medicare beneficiaries aged 65 years and older. Surveys are conducted each year through in-person interviews. Vision-related tests of distance acuity, near-distance acuity, and contrast sensitivity are conducted with the aid of a computer tablet. Because participants wear their usual eyewear for vision assessments, acuity estimates are based on presenting acuity. 

These data are also available in the VEHSS Data Explorer, and interactive data visualization tool reporting prevalence information from more than 10 data sources: https://www.cdc.gov/vision-health-data/index.html
NNDSS - Table III. Tuberculosis

NNDSS - Table III. Tuberculosis - 2018.This Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying WONDER data.  Data on United States will exclude counts from US territories. 
 
Footnote: C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable    Cum: Cumulative year-to-date counts.    Min: Minimum.    Max: Maximum. 

* Case counts for reporting year 2017 and 2018 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf 

† Data for TB are displayed quarterly.
NNDSS - TABLE 1U. Leptospirosis to Listeriosis, Probable

NNDSS - TABLE 1U. Leptospirosis to Listeriosis, Probable - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Beginning in 2020, confirmed and probable cases are published separately. Prior years included confirmed cases only.
Compound 529486: Propanoic acid, 3-[N-(2-acetyl-1-pyrrolyl)]

Chemical compound data from PubChem database. IUPAC Name: 3-(2-acetylpyrrol-1-yl)propanoic acid. Molecular Formula: C9H11NO3. Molecular Weight: 181.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2015 CMHS Uniform Reporting System (URS) Table for Wyoming

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Wyoming.  The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 530212: Melatonin, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl N-[2-(5-methoxy-1-trimethylsilylindol-3-yl)ethyl]ethanimidate. Molecular Formula: C19H32N2O2Si2. Molecular Weight: 376.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.